Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
1. A method of treating advanced renal cell carcinoma with or without bone or visceral metastases in a human patient who has received prior anti-angiogenic therapy, comprising administering to the patient an amount of cabozantinib or a pharmaceutically acceptable salt thereof, wherein progression-free survival (PFS) and one or both of overall survival (OS) and objective response rate (ORR) are extended as compared to patients who have received prior anti-angiogenic therapy, wherein the prior anti-angiogenic therapy is selected from the group consisting of axitinib, pazopanib, sorafenib, sunitinib, everolimus, temsirolimus, bevacizumab, interleukins, interferon-α, and peginterferon.
2. The method of claim 1 , wherein the cabozantinib is administered as cabozantinib (S)-malate.
3. The method of claim 2 , wherein cabozantinib (S)-malate is administered in an amount sufficient to achieve a median time to peak plasma concentration (Tmax) of from approximately 2 to 5 hours post-dose; and a Cmax of 200 to 500 ng/mL.
4. The method of claim 1 , wherein the prior antiangiogenic therapy is selected from the group consisting of axitinib, pazopanib, sorafenib, sunitinib, everolimus, temsirolimus, and bevacizumab.
5. The method of claim 4 , wherein the prior anti-angiogenic therapy is everolimus.
6. The method of claim 2 , wherein cabozantinib (S)-malate is administered as a tablet comprising cabozantinib (S)-malate, microcrystalline cellulose, anhydrous lactose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide magenisum stearate, and film coating comprising hypromellose, titanium dioxide, triacetin, and iron oxide yellow.
7. The method of claim 2 , wherein the cabozantinib (S)-malate is administered as a tablet formulation comprising approximately:
30-32 percent by weight of cabozantinib, (S)-malate salt;
38-40 percent by weight of microcrystalline cellulose;
18-22 percent by weight of lactose;
2-4 percent by weight of hydroxypropyl cellulose;
4-8 percent by weight of croscarmellose sodium;
0.2-0.6 percent by weight of colloidal silicon dioxide;
0.5-1 percent by weight of magnesium stearate; and further comprising:
a film coating material comprising hypromellose, titanium dioxide, triacetin, and iron oxide yellow;
or wherein the cabozantinib (S)-malate is administered as a tablet formulation comprising approximately (% w/w):
31-32 percent by weight of cabozantinib, (S)-malate salt;
39-40 percent by weight of microcrystalline cellulose;
19-20 percent by weight of lactose;
2.5-3.5 percent by weight of hydroxypropyl cellulose;
5.5-6.5 percent by weight of croscarmellose sodium;
0.25-0.35 percent by weight of colloidal silicon dioxide;
0.7-0.8 percent by weight of magnesium stearate; and further comprising:
3.9-4.1 percent by weight of a film coating material comprising hypromellose, titanium dioxide, triacetin, and iron oxide yellow.
8. The method of claim 2 , wherein cabozantinib (S)-malate is administered as a tablet formulation containing 20, 40, or 60 mg of cabozantinib.
9. The method of claim 8 , wherein cabozantinib (S)-malate is administered as a tablet formulation selected from the group consisting of:
Theoretical Quantity (mg/unit dose)
20-mg
40-mg
60-mg
Ingredient
Tablet*
Tablet*
Tablet*
Cabozantinib (S)-malate
25.34
50.69
76.03
Microcrystalline Cellulose, PH-102
31.08
62.16
93.24
Lactose Anhydrous, 60M
15.54
31.07
46.61
Hydroxypropyl Cellulose, EXF
2.400
4.800
7.200
Croscarmellose Sodium
4.800
9.600
14.40
Colloidal Silicon Dioxide
0.2400
0.4800
0.7200
Magnesium Stearate (Non-Bovine)
0.6000
1.200
1.800
Opadry ® Yellow (03K92254)
3.200
6.400
9.600
Total tablet weight
83.20
166.4
249.6.
*Free Base Equivalent (FBE)
10. The method of claim 2 , wherein the cabozantinib (S)-malate is administered once daily.
11. The method of claim 10 , wherein the amount of cabozantinib that is administered once daily is 60 mg.
12. The method of claim 2 , wherein the amount of cabozantinib (S)-malate is sufficient to achieve a median time to peak plasma concentration (Tmax) from 3.2 to 3.8 hours post-dose; and a mean Cmax of 310 to 350 ng/mL.
13. The method of claim 1 , wherein the overall survival of the patient is extended as compared to patients taking everolimus, or the objective response rate of the patient is extended as compared to patients taking everolimus, or both the overall survival and the objective response rate of the patient are extended as compared to patients taking everolimus.
14. The method of claim 2 , wherein an amount of cabozantinib (S)-malate is sufficient to achieve one, two, three, four, five, six, seven, or eight effects selected from the group consisting of:
a median time to peak plasma concentration (Tmax) from 2 to 5 hours post-dose;
a Cmax of 200 to 500 ng/mL;
an AUC 0-24 of 2500 to 5200 ng*h/mL;
an AUC 0-t of 18,000 to 42,000 ng*h/mL;
an AUC 0-∞ of 19,000 to 45,000 ng*h/mL;
an oral volume distribution (Vz/F) of 100 to 600 L;
a terminal half-life of 90 to 135 h; and
a clearance at steady state (CL/F) of 0.7 to 3.9 L/h;
wherein the cabozantinib (S)-malate is administered as a tablet formulation comprising approximately (% w/w):
31-32 percent by weight of cabozantinib, (S)-malate salt;
39-40 percent by weight of microcrystalline cellulose;
19-20 percent by weight of lactose;
2.5-3.5 percent by weight of hydroxypropyl cellulose;
5.5-6.5 percent by weight of croscarmellose sodium;
0.25-0.35 percent by weight of colloidal silicon dioxide;
0.7-0.8 percent by weight of magnesium stearate; and further comprising:
3.9-4.1 percent by weight of a film coating material comprising hypromellose, titanium dioxide, triacetin, and iron oxide yellow.
15. The method of 14 , wherein cabozantinib (S)-malate is administered as a tablet formulation containing 20, 40, or 60 mg of cabozantinib.
16. The method of claim 2 , wherein the cabozantinib (S)-malate is administered in an amount sufficient to achieve one, two, three, four, five, six, seven, or eight effects selected from the group consisting of:
a median time to peak plasma concentration (Tmax) from 2 to 5 hours post-dose;
a Cmax of 200 to 500 ng/mL;
an AUC 0-24 of 2500 to 5200 ng*h/mL;
an AUC 0-t of 18,000 to 42,000 ng*h/mL;
an AUC 0-∞ of 19,000 to 45,000 ng*h/mL;
an oral volume distribution (Vz/F) of 100 to 600 L;
a terminal half-life of 90 to 135 h; and
a clearance at steady state (CL/F) of 0.7 to 3.9 L/h.
17. The method of claim 2 , wherein the cabozantinib (S)-malate is administered in an amount sufficient to achieve one, two, three, four, five, six, seven, or eight effects selected from the group consisting of:
a median time to peak plasma concentration (Tmax) from 2.5 to 4.5 hours post-dose;
a Cmax of 250 to 450 ng/mL;
an AUC 0-24 of 3000 to 4700 ng*h/mL;
an AUC 0-t of 23,000 to 37,000 ng*h/mL;
an AUC 0-∞ of 24,000 to 40,000 ng*h/mL;
an oral volume distribution (Vz/F) of 150 to 550 L;
a terminal half-life of 100 to 125 h; and
a clearance at steady state (CL/F) of 1.2 to 3.2 L/h.
18. The method of claim 2 , wherein the cabozantinib (S)-malate is administered in an amount sufficient to achieve one, two, three, four, five, six, seven, or eight effects selected from the group consisting of:
a median time to peak plasma concentration (Tmax) from 3 to 4 hours post-dose;
a Cmax of 300 to 400 ng/mL;
an AUC 0-24 of 3500 to 4200 ng*h/mL;
an AUC 0-t of 28,000 to 32,000 ng*h/mL;
an AUC 0-∞ of 29,000 to 35,000 ng*h/mL;
an oral volume distribution (Vz/F) of 200 to 500 L;
a terminal half-life of 110 to 115 h; and
a clearance at steady state (CL/F) of 1.2 to 3.2 L/h.
19. The method of claim 2 , wherein the cabozantinib (S)-malate is administered in an amount sufficient to achieve one, two, three, four, five, six, seven, or eight effects selected from the group consisting of:
a median time to peak plasma concentration (Tmax) from 3.2 to 3.8 hours post-dose;
a Cmax of 310 to 350 ng/mL;
an AUC 0-24 of 3700 to 4000 ng*h/mL;
an AUC 0-t of 29,000 to 30,000 ng*h/mL;
an AUC 0-∞ of 30,000 to 33,000 ng*h/mL;
an oral volume distribution (Vz/F) of 300 to 400 L;
a terminal half-life of 110 to 114 h; and
a clearance at steady state (CL/F) of 2 to 3 L/h.
20. A method of treating advanced renal cell carcinoma in human patients who have received prior anti-angiogenic therapy, comprising administering to the patient cabozantinib or a pharmaceutically acceptable salt thereof, wherein the overall survival of the patients are extended as compared to the median overall survival of patients who have received prior anti-angiogenic therapy, wherein the prior anti-angiogenic therapy is selected from the group consisting of axitinib, pazopanib, sorafenib, sunitinib, everolimus, temsirolimus, bevacizumab, interleukins, interferon-α, and peginterferon.
21. A method of treating advanced renal cell carcinoma with bone or visceral metastases in a human patient who has received prior anti-angiogenic therapy, comprising administering to the patient an amount of cabozantinib or a pharmaceutically acceptable salt thereof, wherein progression-free survival (PFS) and one or both of overall survival (OS) and objective response rate (ORR) are extended as compared to patients who have received prior anti-angiogenic therapy, wherein the prior anti-angiogenic therapy is selected from the group consisting of axitinib, pazopanib, sorafenib, sunitinib, everolimus, temsirolimus, bevacizumab, interleukins, interferon-α, and peginterferon.